Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Day One Biopharmaceuticals Inc
(NQ:
DAWN
)
12.43
+0.14 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Day One Biopharmaceuticals Inc
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
November 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 30, 2023
Priority review granted with PDUFA target action date of April 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
August 07, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Pricing of Public Offering of Common Stock
June 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Proposed Public Offering of Common Stock
June 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
June 04, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
May 30, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
May 01, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
April 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
March 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
January 08, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 17, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
November 11, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
November 07, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
October 17, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.